By 2020, DNDi aims to deliver from its Chagas-specific portfolio:

  • An effective and safe new oral treatment regimen of chronic indeterminate Chagas disease, ideally also effective against the acute form of the disease
  • Biomarkers to gain understanding of disease progression and ease the development of tools for evaluation of treatment response to support drug development

 

The current Chagas disease portfolio includes:

 Research

Research

Chagas H2L
Chagas Lead Optimization
Biomarkers

 Translation

Translation

Fexinidazole
New Benznidazole Regimens +/- Fosravuconazole
Biomarkers 

 Implementation

Implementation

Benznidazole Paediatric Dosage Form

 

 

For more details on each project, see DNDi‘s Global Portfolio